Table 1 General and disease characteristics as well as endothelial function scores for patients in the cross-sectional study
| Â | RA patients | Number |
|---|---|---|
General characteristics | Â | Â |
   Sex female n (%) | 72 (73) | 99 |
Disease characteristics | Â | Â |
   RF positive n (%) | 70 (78) | 90 |
   Disease duration (years) | 11 ± 10 | 74 |
   ESR (mm/hr) | 17.0 (8.8-28.3) | 90 |
   CRP (mg/L) | 5.0 (2.9-13.50) | 93 |
   DAS28 | 3.6 ± 1.3 | 93 |
   HAQ | 1.7 ± .87 | 95 |
RA medications | Â | Â |
   Methotrexate n (%) | 60 (60) | 99 |
   Prednisolone n (%) | 22 (22) | 99 |
   NSAIDS n (%) | 18 (18) | 99 |
   Cyclooxygenase II inhibitors n (%) | 11 (11) | 99 |
   Anti-TNF-α therapy n (%) | 11 (11) | 99 |
CVD medications | Â | Â |
   Antihypertensive n (%) | 25 (25) | 99 |
   Antihypercholesterolemic n (%) | 12 (12) | 99 |
   Beta-blocker n (%) | 7 (7) | 99 |
   Calcium channel blocker n (%) | 5 (5) | 99 |
Microvascular function | Â | Â |
Endothelium-dependent (ACh%) | 236 (152-407) | 94 |
Endothelium-independent (SNP%) | 261 (181-384) | 94 |
Macrovascular function | Â | Â |
Endothelium-dependent (FMD%) | 9.5 (4.8-13.5) | 96 |
Endothelium-independent (GTN%) | 24.0 (16.3-30.4) | 93 |